Join the DDA or

Ranitidine recall

Contaminant risk investigation continues

November 20th 2019

Tagged: MHRA alert

By Ailsa Colquhoun

Creo Pharma Ltd and Tillomed Laboratories Limited are recalling all unexpired stock of the following ranitidine lines

The products are:

  • Creo Pharma Limited (Zentiva Pharma UK Ltd) – Ranitidine oral solution 30mg/ml – PL 31862/0023
  • Tillomed Laboratories Limited – Ranitidine 150mg tablets – PL 11311/0138

The recall is a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.

Healthcare professionals are asked to quarantine all remaining stock and return it to the supplier.

Patients taking affected ranitidine medication should be advised to continue as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment

Investigation into other potentially impacted products is continuing.

  • For stock control enquiries please contact Zentiva customer service team on +44 (0) 844 8793 188 or GFD-CUSTOMERSERVICES@zentiva.com
  • For medical information enquiries please contact Zentiva medical information team on +44 (0) 800 090 2408 or UKMedInfo@zentiva.com

 

For all the latest news of the 2020 DDA annual conference...

Learn more